4 results
To determine the clinical efficacy and toxicity of ABT-869 in combination with paclitaxel in the first-line treatment of subjects with metastatic breast cancer.
Primary objective:To evaluate the objective response rate (ORR) of AZD1775 in combination with gemcitabine, carboplatin, paclitaxel,or PLD in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancerSecondary…
The purpose of this study is to evaluate how safe telisotuzumab vedotin is and how telisotuzumab vedotin is tolerated as monotherapy and in combination with osimertinib.
Phase 1• To determine the maximum tolerated dose (MTD) and RP2D of BLU 945 as monotherapy and in combination with osimertinib• To determine the safety and tolerability of BLU 945 as monotherapy and in combination with osimertinibPhase 2• To assess…